Genovis AB (publ.) (GENO) - Total Liabilities
Based on the latest financial reports, Genovis AB (publ.) (GENO) has total liabilities worth Skr106.41 Million SEK (≈ $11.45 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genovis AB (publ.) - Total Liabilities Trend (2008–2025)
This chart illustrates how Genovis AB (publ.)'s total liabilities have evolved over time, based on quarterly financial data. See GENO net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Genovis AB (publ.) Competitors by Total Liabilities
The table below lists competitors of Genovis AB (publ.) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kross Ltd
NSE:KROSS
|
India | Rs1.49 Billion |
|
Brand Engagement Network Inc
NASDAQ:BNAI
|
USA | $9.03 Million |
|
SB Financial Group Inc
NASDAQ:SBFG
|
USA | $1.40 Billion |
|
Bank Mnc Internasional Tbk
JK:BABP
|
Indonesia | Rp17.35 Trillion |
|
GPT Healthcare Ltd
NSE:GPTHEALTH
|
India | Rs1.95 Billion |
|
Arsan Tekstil Ticaret ve Sanayi AS
IS:ARSAN
|
Turkey | TL1.31 Billion |
|
Katmerciler Arac Ustu Ekipman Sanayi ve Ticaret AS
IS:KATMR
|
Turkey | TL4.66 Billion |
|
Baozun Inc
F:2BZA
|
Germany | €4.20 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Genovis AB (publ.)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GENO company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 5.81 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genovis AB (publ.)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genovis AB (publ.) (2008–2025)
The table below shows the annual total liabilities of Genovis AB (publ.) from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr106.41 Million ≈ $11.45 Million |
+7.01% |
| 2024-12-31 | Skr99.44 Million ≈ $10.70 Million |
+1.42% |
| 2023-12-31 | Skr98.05 Million ≈ $10.55 Million |
+294.27% |
| 2022-12-31 | Skr24.87 Million ≈ $2.68 Million |
-10.41% |
| 2021-12-31 | Skr27.76 Million ≈ $2.99 Million |
+42.47% |
| 2020-12-31 | Skr19.48 Million ≈ $2.10 Million |
+45.14% |
| 2019-12-31 | Skr13.42 Million ≈ $1.44 Million |
+14.18% |
| 2018-12-31 | Skr11.76 Million ≈ $1.27 Million |
+44.80% |
| 2017-12-31 | Skr8.12 Million ≈ $873.71K |
+28.74% |
| 2016-12-31 | Skr6.31 Million ≈ $678.66K |
-22.07% |
| 2015-12-31 | Skr8.09 Million ≈ $870.86K |
+62.52% |
| 2014-12-31 | Skr4.98 Million ≈ $535.83K |
-40.46% |
| 2013-12-31 | Skr8.36 Million ≈ $900.00K |
+84.81% |
| 2012-12-31 | Skr4.53 Million ≈ $487.00K |
+31.88% |
| 2011-12-31 | Skr3.43 Million ≈ $369.28K |
+32.70% |
| 2010-12-31 | Skr2.59 Million ≈ $278.29K |
-33.73% |
| 2009-12-31 | Skr3.90 Million ≈ $419.91K |
-53.23% |
| 2008-12-31 | Skr8.34 Million ≈ $897.78K |
-- |
About Genovis AB (publ.)
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an… Read more